Skip to content
Open access

Cardiac troponin elevations and risk of major adverse cardiovascular events in five non-cardiac diseases

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

In patients with non-cardiac diseases, hs-cTnT elevations were significantly more prevalent than hs-cTnI elevations, suggesting distinct underlying mechanisms of myocardial injury and supporting a disease-specific of troponin elevations beyond ACS.

Abstract

Cardiac troponins (cTn) are biomarkers of myocardial injury and a cornerstone in the diagnosis of acute coronary syndrome (ACS); However, cTn elevations are frequently observed in non-cardiac diseases and have been associated with adverse outcomes. The prognostic implications and differences between high-sensitivity cardiac troponin T (hs-cTnT) and I (hs-cTnI) remain incompletely understood. Data on the comparative prognostic performance of cTnT and cTnI across disease states in patients with paired measurements are limited. To investigate the prevalence and prognostic value of hs-cTnT and hs-cTnI in five non-cardiac disease groups and to compare their relative prognostic performance. We prospectively included patients with five non-cardiac conditions: chronic kidney disease stage 5 (CKD5), rhabdomyolysis, sepsis, stroke, and major orthopedic surgery, over a 1.5-year period. Patients were enrolled within 48 hours of admission and underwent ECG, echocardiography, and measurement of hs-cTnT and hs-cTnI . The primary endpoint was major adverse cardiovascular events (MACE) defined as all-cause mortality, myocardial infarction, or stroke. Secondary endpoints included prevalence of cTn elevation defined as >99th percentile. Cox proportional hazards models were used to evaluate associations between cTn levels and MACE. cTn concentrations were log2-transformed to model risk per doubling, with analyses performed separately and with mutual adjustment for the other troponin. Among 226 patients (mean age 73.6±14.1 years; 49.6% female), 166 (73.5%) had hs-cTnT above the sex-specific 99th percentile compared with 45 (19.9%) with elevated hs-cTnI (p<0.001). Distribution of cTn elevations across disease groups are shown in fig 1. During a median follow-up of 1.44 years (IQR 1.09–1.86; reverse Kaplan–Meier), 29 patients (12.8%) experienced MACE: 25 (11.1%) died, 7 (3.1%) had a stroke, and none had myocardial infarction. In the overall cohort, both hs-cTnT and hs-cTnI were associated with incident MACE in separate models (hs-cTnT: HR 1.33 [1.15–1.54]; hs-cTnI: HR 1.13 [1.03–1.24] per doubling). In mutually adjusted models, hs-cTnT remained independently associated with MACE (HR 1.36 [1.10–1.69]), whereas hs-cTnI did not (HR 0.98 [0.86–1.12]) (fig 2). In subgroup analyses, the associations differed across disease groups. In CKD5, hs-cTnT was associated with MACE (HR 2.21 [1.33–3.67]), whereas in stroke, hs-cTnI was (HR 1.98 [1.10–3.56]) and hs-cTnT was not. In patients with non-cardiac diseases, hs-cTnT elevations were significantly more prevalent than hs-cTnI elevations. Both cTnI and cTnT were associated with subsequent MACE. Notably, hs-cTnT and hs-cTnI demonstrated differential prognostic patterns across disease states, suggesting distinct underlying mechanisms of myocardial injury and supporting a disease-specific interpretation of troponin elevations beyond ACS.Figure 1Figure 2

Read PDF

Similar papers

Open access Oct 2026

High-sensitivity troponin-T concentrations and risk of heart failure in patients with acute pulmonary embolism

High-sensitivity cardiac troponins are the gold-standard biomarkers for diagnosing myocardial injury. We have previously shown that elevated high-sensitivity troponin-T (hsTnT) is associated with both short- and long-term mortality in patients with acute pulmonary embolism (PE). However, it is unknown whether hsT...

C. Byrne, M. Afzal, J. Frary et al. · 0 citations
Open access Oct 2026

Cardiac troponin I and T transcripts are detectable in skeletal muscle of patients hospitalized with non-cardiac disease

Cardiac troponins (cTn) are central to the diagnosis of acute coronary syndrome. Fulfilment of the criteria for myocardial injury (cTn>99th percentile) is common in non-cardiac diseases and cTn-release mechanisms remain incompletely understood. Cardiac troponin T (cTnT) release from skeletal muscle has been demon...

S. Knudsen, R. Hasselbalch, N. Strandkjær et al. · 0 citations
Open access Oct 2026

Long forms of cardiac troponin T in non-cardiac diseases with frequent troponin T elevations

Elevations of cardiac troponin (cTn), particularly cardiac troponin T (cTnT), are common in non-cardiac diseases and may complicate clinical decision making and potentially lead to unnecessary invasive procedures. The currently used commercial high-sensitivity cTnT (hs-cTnT) assay detects all circulating cTnT mol...

S. Knudsen, R. Hasselbalch, N. Strandkjær et al. · 0 citations
Open access Oct 2026

The concentration of long cardiac troponin T forms is independent of age and common comorbidities in patients referred for elective open-heart surgery

High-sensitivity cardiac troponin T (hs-cTnT) is a cornerstone of the diagnosis of myocardial infarction (MI), but mild elevations of hs-cTnT are common also in chronic cardiac conditions. Early troponin release in type 1 MI is dominated by large cTnT-I-C complexes, yet the current commercial hs-cTnT assay detect...

T. Tuominen, K. Airaksinen, J. Lehto et al. · 0 citations
Open access Nov 2026

23 A Rising High Sensitivity Troponin Trend in Medical Intensive Care Unit Patients Predicts Unfavorable Outcomes

Cardiac troponins (cTns) are sensitive and specific biomarkers for cardiomyocyte injury, and their temporal quantification is a critical diagnostic consideration for acute myocardial infarction (AMI). The enhanced analytical sensitivity of modern cTn assays has revealed that myocardial injury is common in other c...

Stephen P. Gadomski, Andrea L. Nixon, Fatemeh Sajedieanfard et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.